Format

Send to

Choose Destination
Eur J Endocrinol. 2019 Sep 1. pii: EJE-19-0458.R1. doi: 10.1530/EJE-19-0458. [Epub ahead of print]

IGF-1 and IGF-1 SDS - fit for purpose?

Author information

1
S Kos, Department of Clinical Chemistry, Maasstad Hospital, Rotterdam, Netherlands.
2
C Cobbaert, Clinical Chemistry and Laboratory Medicine, Leiden University Medical Center, Leiden, Netherlands.
3
M Kuijper, Department of Science, Maasstad Hospital, Rotterdam, Netherlands.
4
W Oostdijk, Pediatrics, J6-S, Leiden University Medical Center, Leiden, 2300 RC, Netherlands.
5
S Hannema, Dept of Pediatrics, Leiden University Medical Center, Leiden, 2300 RC, Netherlands.
6
J Wit, Pediatrics, Leiden University Medical Center, Leiden, 2300 RC, Netherlands.
7
N Biermasz, Endocrinology, Leiden University Medical Center, Leiden, 2381 JJ, Netherlands.
8
B Ballieux, Chemical Laboratory, Leiden University Medical Centre, Leiden, Netherlands.

Abstract

Three recent publications in this journal have reported that the differences in IGF-1 normative data significantly impact the classification of patients with growth hormone (GH)- excess and deficiency disorders in such a way that clinical performance is severely flawed. This concerns not only pediatric but also adult patients. With this letter, we aim to address additional issues, not previously addressed, which add to the complexity of the interpretation of IGF-1 results. Specifically, the relation between analytical performance of IGF-1 assays and acceptable clinical performance is discussed.

PMID:
31505458
DOI:
10.1530/EJE-19-0458

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center